Tango Therapeutics, INC Form 4 insider transactions

Adam Crystal, President, R&D of Tango Therapeutics, Inc., sold 27,000 shares of common stock on August 3, 2026.

Tango Therapeutics President of R&D, Adam Crystal, reported transactions involving the sale of company stock and the acquisition of stock options under a pre-arranged trading plan.

Director John Ketchum received an equity grant of 4,000 restricted stock units and 25,000 stock options from Tango Therapeutics.

Director Lesley Ann Calhoun received an equity grant of 4,000 restricted stock units and 25,000 stock options from Tango Therapeutics.

Director Mace Rothenberg was granted 4,000 restricted stock units and 25,000 stock options by Tango Therapeutics.

Director Sung Lee received an equity grant of restricted stock units and stock options from Tango Therapeutics.

Adam Crystal, President of R&D at Tango Therapeutics, exercised options and sold 27,000 shares under a 10b5-1 plan.

Tango Therapeutics President of R&D Adam Crystal exercised stock options and sold 27,000 shares under a 10b5-1 plan.

Tango Therapeutics CFO Matthew Gall was granted 40,000 restricted stock units and 240,000 stock options as part of a compensation package.

Director Sung Lee received a grant of 12,300 restricted stock units and 5,200 stock options as part of director compensation.

Adam Crystal, President of R&D at Tango Therapeutics, exercised options and sold 38,460 shares under a 10b5-1 plan.

Adam Crystal, President of R&D at Tango Therapeutics, executed a Rule 10b5-1 trading plan, acquiring 27,000 shares and selling 27,000 shares.

Tango Therapeutics' President of R&D, Adam Crystal, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

Adam Crystal, President of R&D at Tango Therapeutics, Inc., sold 54,345 shares of common stock under a pre-arranged 10b5-1 trading plan.

Tango Therapeutics' Chief Financial Officer, Daniella Beckman, reported the acquisition of restricted stock units and stock options, alongside sales of common stock to cover tax obligations.

Barbara Weber, Tango Therapeutics' Director and Executive Chair, acquired new restricted stock units and stock options, while also selling shares to cover tax obligations.

Adam Crystal, President of R&D at Tango Therapeutics, acquired new restricted stock units and stock options while selling shares to cover tax obligations.

Tango Therapeutics' President and CEO, Malte Peters, received substantial equity awards, including restricted stock units and stock options, aligning his interests with long-term company performance.

Tango Therapeutics Director Sung Lee receives 10,000 restricted stock units and 60,000 stock options.

Tango Therapeutics Director Malte Peters was granted 150,000 stock options with an $8.01 exercise price, vesting over four years.

Third Rock Ventures IV, L.P., a 10% owner and director, sold 477,401 shares of Tango Therapeutics, Inc. common stock for approximately $4.84 million.

Third Rock Ventures IV, a significant shareholder and director group, reported the sale of 500,000 shares of Tango Therapeutics common stock for approximately $4 million.

Third Rock Ventures IV, L.P., a 10% owner and director, sold 363,541 shares of Tango Therapeutics common stock for a weighted average price of $7.04 per share.

Third Rock Ventures, a 10% owner and director, reported sales of Tango Therapeutics common stock totaling 729,365 shares in early September 2025 under a Rule 10b5-1 plan.

Third Rock Ventures, a 10% owner and director of Tango Therapeutics, sold 302,194 shares of common stock for approximately $2.1 million.

Third Rock Ventures, a 10% owner and director of Tango Therapeutics, Inc., reported the sale of 1.1 million common shares for approximately $7.71 million.

Tango Therapeutics, Inc. Director Malte Peters was granted 6,250 restricted stock units and options to purchase 37,500 shares of common stock on June 5, 2025, as part of his compensation.

Tango Therapeutics, Inc. Director Lesley Ann Calhoun reported the acquisition of 6,250 restricted stock units and 37,500 stock options on June 5, 2025, as part of her compensation.

Tango Therapeutics Director Mace Rothenberg has reported the acquisition of 6,250 restricted stock units and 37,500 stock options, signaling new equity compensation.

Tango Therapeutics, Inc. Director John B. Ketchum has increased his beneficial ownership in the company through the acquisition of 6,250 restricted stock units and 37,500 stock options.